ANGO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANGO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. AngioDynamics's interest expense for the three months ended in Feb. 2024 was $ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.9 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. AngioDynamics's Operating Income for the three months ended in Feb. 2024 was $ -11.6 Mil. AngioDynamics's Interest Expense for the three months ended in Feb. 2024 was $ 0.0 Mil. AngioDynamics has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical data trend for AngioDynamics's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AngioDynamics (NAS:ANGO) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
AngioDynamics's Interest Expense for the three months ended in Feb. 2024 was $0.0 Mil. Its Operating Income for the three months ended in Feb. 2024 was $-11.6 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Feb. 2024 was $0.0 Mil.
AngioDynamics's Interest Coverage for the quarter that ended in Feb. 2024 is calculated as
AngioDynamics had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Lorinda Burgess | director | 22 WEST FRONTAG ROAD, NORTHBROOK IL 60093 |
Karen A Licitra | director | C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050 |
Michael E Tarnoff | director | C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110 |
Scott Centea | officer: SVP/GM, VIT | C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110 |
Dave Helsel | officer: SVP Global Operations and R&D | 400 WOOD ROAD, BRAINTREE MA 02184 |
Laura Piccinini | officer: SVP International | C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110 |
Stephen A Trowbridge | officer: SVP and General Counsel | 14 PLAZA DRIVE, LATHAM NY 120110 |
James C Clemmer | director, officer: President and CEO | COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048 |
Wesley Johnson | director | |
Chad Thomas Campbell | officer: SVP/GM, Vascular Access | 140 POKANOKET PATH, WRENTHAM MA 02093 |
Warren Jr Nighan | officer: SVP Quality and Regulatory | ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110 |
Richard C Rosenzweig | officer: SVP and General Counsel | C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277 |
Kevin J Gould | director | 247 WASHINGTON STREET, DUXBURY MA 02332 |
Brent J. Boucher | officer: SVP and GM of Oncology | 14 PLAZA DRIVE, LATHAM NY 12110 |
Michael Greiner | officer: EVP and CFO | C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421 |
From GuruFocus
By Business Wire • 08-03-2023
By GuruFocus Research • 01-05-2024
By Business Wire • 12-21-2023
By Business Wire Business Wire • 05-03-2022
By Business Wire Business Wire • 04-04-2022
By Business Wire • 10-04-2023
By Business Wire • 08-15-2023
By Business Wire Business Wire • 05-16-2022
By Business Wire Business Wire • 06-20-2023
By Business Wire Business Wire • 03-08-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.